Double-Hit Lymphoma - ARare Subset of Diffuse Large B Cell Lymphoma with Poor Outcome.
Double-hit lymphoma (DHL) has been identified as a subset of diffuse large B-cell lymphoma with poor clinical outcomes. It is because of genetic translocation of C-myc and Bcl2 gene that make it more aggressive and un-responsive to conventional and salvage treatments. DHLis an extremely rare entity of non-Hodgkin's lymphoma (NHL) having no established incidence data so far. In literature very limited data is available to guide therapeutic decisions and despite aggressive chemotherapy followed by autologus hematopoietic cell transplantation, outcomes still remain poor. Herein, we report a case of 82-year Pakistani patient who presented with left groin lump. Incision biopsy established the diagnosis of DHL. Despite intensive course of standard chemotherapy and radiation therapy, he died with progression of disease.
Department of Radiation Oncology, Institute of Nuclear Medicine, Oncology and Radiotherapy (INOR), Abbottabad.
Sajid
S
Zaman
Department of Radiation Oncology, Institute of Nuclear Medicine, Oncology and Radiotherapy (INOR), Abbottabad.
Jawad A
JA
Gillani
Department of Radiation Oncology, Institute of Nuclear Medicine, Oncology and Radiotherapy (INOR), Abbottabad.
Rashid
R
Rasheed
D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017809:Fatal Outcome; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D035583:Rare Diseases